Laboratorios Rovi registers net profit of EUR 46.8m for the first nine months of the year, up 53% compared to 2019
Laboratorios Rovi registra un beneficio neto de EUR 46,8m en los nueve primeros meses del año, un 53% más con respecto a 2019
Intel ID : 304970
Relevant Documents
| Notice / Relevant Fact | 05 Nov 2020 | Laboratorios_Rovi_Hecho_Relevante_2020.pdf | ES |
|
| Intel ID | 304970 | |
| Value | EUR 46,80m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Laboratorios Rovi
(31 Dec 2023) |
Revenue: EUR 852,71m EBITDA: EUR 244,59m Net Debt: EUR 41,54m People: 2111 |
|
| Date |
 |
|
| Country | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
 |
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.